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nel during standard-of-care visits. Although this is the traditional approach, it has 
several practical shortcomings: infrequent or irregular standard-of-care visits; 
patients switching health care providers; transient nature of some safety events; 
treatment at non-study sites, and the lack of care-seeking for the safety events. An 
alternative study design that overcomes several of these shortcomings includes 
direct-to-patient contact (DPC) and follow-up. Objectives: The purpose of this 
study is to describe patients’ short and long term management patterns including 
the detection and verification of events of interest by contacting patients’ event 
treating physician (ETP). MethOds: This is multinational multicenter observational 
prospective longitudinal cohort study involving 10,600 patients in Europe and South 
America. Patients were enrolled at hospital and followed up by telephone by a spe-
cialized DPC unit at 6 weeks then quarterly up to 2 years after hospital discharge. 
Data collected include clinical outcomes, safety events of interest, economic bur-
den and quality of life. Results: A total of 88,276 phone calls to patients were 
performed, achieving a reachable rate of 88.5% and an interview successful rate of 
84.6%. 87.2% of the initial sample completed the 2-year follow-up period: 5.7% of 
the sample died, 6.0% voluntarily withdrew and 0.9% was withdrawn to participate 
to a clinical trial. Only 19 patients were never reached (0.2%). In total, 2144 events of 
interest were detected and a medical verification from ETPs was obtained in 72.3% of 
the case. cOnclusiOns: This study demonstrates that DPC along with a proactive 
pharmacovigilance system achieved very high response rates from both patients 
and ETPs. It represents an effective alternative methodology to collect patients data, 
including safety data, in real life settings.
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Objectives: Atrial fibrillation (AF) is frequent in acute coronary syndromes (ACS) 
and impacts the need for subsequent antithrombotic treatment. However, whether 
associations of antithrombotic treatment with strokes, bleeding, and death differ 
between ACS patients with and without AF remains uncertain. MethOds: Olmsted 
County, MN residents with incident myocardial infarction or unstable angina during 
2005-2010 were classified according to AF status prior to or during the index ACS 
hospitalization. Antithrombotic strategy at discharge was categorized into double/
triple vs. no/single and warfarin vs. no warfarin therapy. Cox regression was used 
to examine associations between treatment and strokes, bleeding, and mortality 
and to test whether AF differentially impacted these associations. Models were 
age- and sex-adjusted and weighted for the inverse probability of the propensity 
score for therapy. Results: A total of 244 of 1140 incident ACS patients had AF 
(ACS+AF), and of these patients, 49% were discharged on double/triple antithrom-
botic therapy and 33% received warfarin. In 896 ACS patients without AF, 63% were 
discharged on double/triple therapy and 4% on warfarin. Over a median of 4.2 years, 
95 strokes, 297 bleeds, and 255 deaths occurred. Antithrombotic strategy was not 
associated with the risk of stroke or bleeding. Among all ACS patients, mortality 
was similar between strategies; however, ACS+AF patients on double/triple therapy 
(vs. no/single therapy) showed a trend toward a lower risk of death [HR (95% CI): 
0.64 (0.41-1.02) for ACS+AF, 1.25 (0.83-1.87) for those without AF; pinteraction= 0.03]. 
For warfarin vs. no warfarin, those with AF exhibited a lower mortality risk with 
warfarin [HR (95% CI): 0.46 (0.29-0.73) for ACS+AF, 2.01 (0.94-4.32) for those with-
out AF; pinteraction< 0.01]. cOnclusiOns: Altogether, in community ACS patients, 
antithrombotic strategy is not associated with the risk of stroke, bleeding, or death. 
However, in the subset of ACS patients with AF, a warfarin strategy is associated 
with a lower risk of death.
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Objectives: Determine the impact of co-morbidity in controlling arterial hyperten-
sion in clinical practice situation. MethOds: Cross-sectional study, conducted from 
retrospective review of patient records obtained from primary care. We included 
patients’ ≥ 30 years who demanded attention during the year 2012. The main meas-
ures were: demographics, control (≤ 140/90 mmHg) blood pressure (BP), evolution 
time, co-morbidity (general and specific) protocol using cardiovascular events (CVE), 
visits and referrals to specialists. Statistical analysis and multiple linear regression 
for correction of the models, p< 0.05. Results: We recruited 900 patients (mean age 
67.4 years, women: 51.1%). The 64.8% (CI: 61.7% -67.9%) of subjects had a proper 
control of the BP. The average duration of hypertension was 6.0 years and use 4.6 
protocol entries / year. The average number of visits was 15.3 and 0.7 referrals. The 
years of evolution were associated with age (r = 0.323). The control patients showed 
a higher average BP of ischemic heart disease (11.1% vs. 6.9%) and CVE (19.4% vs. 
14.8%), p < 0.05. The BP control was associated with women (OR = 1.4) and the pres-
ence of CVE (OR = 1.8), p < 0.02. The number of diagnoses (morbidity) was associated 
with age (ß = 0.14) and the number of referrals (ß = 0.08), p < 0.05 (coefficient R2= 
40%). cOnclusiOns: Optimal control of BP is high. The profile of these patients is 
women in a situation of secondary prevention.
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Objectives: International guidelines recommend the use of high dosages statins 
(in particular, Rosuvastatin and Atorvastatin) in high cardiovascular (CV) risk 
patients. The aim of this study was to assess the degree of implementation of the 
while after first year of treatment, controls tend to become less frequent, mostly 
every-three-months (39.9%). When recurrence occurs, main retreatment criteria 
were: presence of macular fluid (93.5%), loss of ETDRS letters (50.5%; 68.8% with 
≥ 5 letters), macular hemorrhage (46.3%) and increase of central-retinal-thickness 
(45.4%). Single injection of anti-VEGF retreatments was applied in 48.6% of recur-
rences, while 23.6% were not treated with anti-VEGF. cOnclusiOns: A relatively 
high adherence to SERV guidelines was followed by Spanish retinologists regarding 
diagnosis, treatment and control of AMD. However, limitations have been identified 
on patterns of follow-up and retreatment criteria that may compromise therapeutic 
and clinical outcomes.
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Objectives: To compare the frequency of injections for ranibizumab and afliber-
cept for the treatment of wet age-related macular degeneration (wAMD) in a real-
world setting. MethOds: Claims from the IMS Integrated Data Warehouse were 
used to identify treatment-naïve patients with wAMD receiving ≥ 1 prescription for 
ranibizumab or aflibercept between 1 November 2011 and 31 March 2012 and with 
a follow-up of 365 days. Patients were considered to be treatment-naïve if they had 
received no anti-VEGF treatment for > 180 days prior to the index date. Mean number 
of injections received within 365 days of treatment initiation and the proportion of 
patients receiving 3 loading doses within 3 months were calculated and compared 
for patients starting therapy with ranibizumab or aflibercept. No adjustments for 
bilateral treatment were performed. Results: Patient characteristics were similar 
for patients receiving ranibizumab (N= 2,799) or aflibercept (N= 117) at the index 
date (median age: 82 years; % male, 36%). The mean (±SD) number of anti-VEGF 
injections received by patients starting on ranibizumab or starting on aflibercept 
was similar: 5.6±3.5 and 5.4±2.8, respectively (p= 0.6593). In patients continuously 
treated with the same agent for 12 months, the mean number of injections was 
also similar across ranibizumab and aflibercept: 4.9±3.4 (n= 1,898) vs 5.2±2.6 (n= 87), 
respectively (p= 0.2705). Approximately two-thirds of patients with more than 3 
injections received 3 loading doses within the first 3 months (ranibizumab, 65.6%; 
aflibercept, 64.3%). Results for patients who were treatment-naïve for 365 days were 
consistent with the above results. cOnclusiOns: There are limited data regard-
ing real-world treatment patterns with aflibercept for the management of wAMD. 
Our results suggest that in routine clinical practice patients receive a comparable 
number of injections in the first year of treatment with both ranibizumab and 
aflibercept. Analysis of data from larger patient populations and for longer follow-
up is warranted when these data become available.
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Objectives: Torsade de pointes (TdP) is an identified risk for antibacterial treat-
ment with macrolides, but the risk might vary across individual macrolides. This 
study evaluates the association between macrolides and TdP from the FDA Adverse 
Event Reporting System (FAERS). MethOds: Disproportionality analysis of FAERS 
between 1997 and 2012 was conducted for azithromycin, clarithromycin, erythro-
mycin and Telithromycin with TdP preferred term of the Medical Dictionary for 
Regulatory Activities using logistic regression. Logistic reporting odds ratio (LROR) 
and corresponding 95% confidence intervals (CIs; LR05-LR95) are estimated for 
individual macrolides. Estimates are compared with Multi-Item Gamma Poisson 
Shrinker data mining algorithm. Estimates ≥ 2 yield significant safety signals. Lack 
of overlap between estimate-specific CIs indicates efficient approach for signal 
detection. Results: A total of 318 TdP events were reported for macrolides. The 
majority of reports were for erythromycin (n= 122) and clarithromycin (n= 114), fol-
lowed by azithromycin (n= 74) and telithromycin (n= 8). Most of events were reported 
for females with median age of 62.8 years. 98% of TdP were serious events (10% of 
those were deaths). Death contributed to 18%, 10% and 5% of serious TdP events 
for azithromycin, erythromycin and clarithromycin, respectively. Telithromycin 
didn’t have death TdP reports. Significant TdP signals were identified for mac-
rolides. LROR (LR05-LR95) were: erythromycin 48.1 (40.4-55.9); clarithromycin 15.3 
(12.1-19.1); azithromycin 13.9 (11.1-17.2); and telithromycin 6.79 (3.20-13.5). Except 
for telithromycin, no overlap was observed between estimate-specific CIs between 
analysis methods. cOnclusiOns: Macrolides are associated with more than 
expected reporting of TdP compared to other drugs and events in the database; 
however, the risk was highest in erythromycin and lowest in telithromycin. Fatal TdP 
was highest in azithromycin, and telithromycin didn’t have fatal TdP. The findings 
show differential risk of TdP across macrolide antibiotics, emphasizing the need for 
monitoring cardiac rhythms in patients treated with macrolides.
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Post-authorization non-interventional safety studies typically enroll patients at 
sites and safety events are reported and collected as appropriate by site person-
